![]()
|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J Biol Chem, Vol. 275, Issue 19, 14440-14445, May 12, 2000
,
,
,
,
**,
, and

From the
Genetics and Aging Research Unit, Department
of Neurology, Massachusetts General Hospital, Harvard Medical School,
Charlestown, Massachusetts 02129, the § Department of
Medicine, Cardiovascular Institute, Mount Sinai School of Medicine,
New York, New York 10029, and the
Department of
Pharmacology, University of Virginia,
Charlottesville, Virginia 22908
| |
ABSTRACT |
|---|
|
|
|---|
Perturbed Ca2+ homeostasis is a
common molecular consequence of familial Alzheimer's disease-linked
presenilin mutations. We report here the molecular interaction of the
large hydrophilic loop region of presenilin 2 (PS2) with sorcin, a
penta-EF-hand Ca2+-binding protein that serves as a
modulator of the ryanodine receptor intracellular Ca2+
channel. The association of endogenous sorcin and PS2 was demonstrated in cultured cells and human brain tissues. Membrane-associated sorcin
and a subset of the functional PS2 complexes were co-localized to a
novel subcellular fraction that is distinctively positive for
calcineurin B. Sorcin was found to interact with PS2 endoproteolytic fragments but not full-length PS2, and the sorcin/PS2 interaction was
greatly enhanced by treatment with the Ca2+ ionophore
A23187. Our findings reveal a molecular link between PS2 and
intracellular Ca2+ channels (i.e. ryanodine
receptor) and substantiate normal and/or pathological roles of PS2 in
intracellular Ca2+ homeostasis.
Nearly half of early-onset familial Alzheimer's disease
(FAD)1 is associated with
mutations in genes encoding two homologous proteins, presenilin 1 (PS1)
and presenilin 2 (PS2) (1). Recent studies have shown that PS1 (and
perhaps PS2) plays an essential role in the Recently, a number of molecules that form complexes with the
presenilins have been identified, including Although the N-terminal and loop domains are not conserved between the
presenilins, FAD mutations have been identified within these regions in
both proteins (1). We have identified the protein sorcin as a PS2
loop-interacting molecule. Sorcin is a penta-EF-hand
Ca2+-binding protein that modulates the ryanodine receptor
(RyR) intracellular calcium channel (39-43) and has previously been
shown to be co-localize with brain RyR in the rat caudate-putamen
nucleus (44). We have found that sorcin interacts with the stable
C-terminal endoproteolytic fragment of PS2 but not with the immature
full-length form. This interaction between sorcin and a subset of the
functional PS2 complexes was modulated by Ca2+ and occurred
in a novel subcellular fraction. Our results reveal a molecular link
between PS2 and intracellular Ca2+ channels, suggesting
that sorcin is involved in the role of PS2 in intracellular
Ca2+ homeostasis.
Expression Constructs--
Molecular cloning of cDNAs
encoding sorcin (40) and grancalcin (45) from an adult human brain
cDNA library was performed using a Marathon-ready rapid
amplification of cDNA ends kit (CLONTECH). Isolated full-length cDNAs were subcloned into the
pcDNA3.1/myc-His mammalian expression vector
(Invitrogen), and the inserts were sequenced using a double-stranded
DNA cycle sequencing system (Life Technologies, Inc.). Inducible
expression constructs (pUHD10-3) coding for wild-type and N141I mutant
versions of PS2 were previously described (32). For the constitutive
expression of PS2, the inserts from the inducible expression constructs
(without FLAG epitope tags) were subcloned into pcDNA3.1/Zeo(+)
(Invitrogen) and were fully verified by sequencing.
Generation of Stable PS2 Cell Lines--
Stable PS2 cell lines
were generated by transfecting SH-SY5Y cells in a 100-mm dish with 5 µg of each plasmid: wild-type PS2, N141I PS2, or vector alone
(pcDNA3.1/Zeo+). Individual zeocin-resistant colonies were isolated
and screened for PS2 expression by Western blotting using Antibodies, Western Blot Analyses, and
Immunoprecipitation--
Protein quantitation, SDS-polyacrylamide gel
electrophoresis (4-20 or 16%), and Western blotting were carried out
as described previously (4, 56). Primary antibodies were used at the
following dilutions: Confocal Microscopy--
Cells grown on glass coverslips or
chamber slides were fixed (4% paraformaldehyde), double-stained with
monoclonal anti-sorcin antibody and Subcellular Fractionation--
Subcellular fractionation of
cultured cells was performed using a protocol that has been previously
described with minor modifications (48, 49). Cells were washed twice
each with ice-cold phosphate-buffered saline and homogenization buffer
(10 mM triethanolamine, 10 mM acetic acid, 250 mM sucrose, 1 mM EDTA, and 1 mM
dithiothreitol) plus protease inhibitor mixture (Roche Molecular
Biochemicals) and homogenized using a 25-gauge needle and a
tight-pestle metal Dounce homogenizer. A post-nuclear supernatant
resulting from low speed centrifugation was separated by differential
centrifugation at 1,000 × g, 14,000 × g, and 100,000 × g to yield post-nuclear supernatant, P2, and P3, respectively. Pooled membrane fractions were
further separated by density gradient centrifugation using step
gradients consisting of 24, 19.33, 14.66, and 10% isotonic Nycodenz
solutions (made in 0.75% NaCl, 10 mM Tris (pH 7.4), 3 mM KCl, and 1 mM EDTA) and were fractionated
using a density gradient fractionator. The fractions were then analyzed
by Western blotting using antibodies to PS2, sorcin, and other marker proteins.
Identification of Sorcin as an Interactor for the Large Hydrophilic
Loop Region of PS2--
To search for putative interacting proteins
for the PS2 loop region, we performed a domain-specific homology search
of GenBankTM. The protein synexin was found to have a high
degree of homology between its N terminus and a portion of the large
hydrophilic loop region of PS2 (Fig.
1A). Synexin, also known as
annexin VII, is a member of the annexin family of calcium- and
phospholipid-binding proteins (50). We then asked whether the protein
sorcin, which has previously been shown to interact with the N-terminal
region of synexin (47), might also interact with the PS2 loop. Sorcin is a member of the family of Ca2+-binding proteins
harboring five EF-hand motifs (40, 41). We first isolated full-length
sorcin cDNA from an adult human brain library and subcloned it into
an expression plasmid encoding the Myc epitope tag; Myc-tagged sorcin
(Myc-sorcin) was then stably transfected into human neuroblastoma SY5Y
cells (Fig. 1B). Western blot analysis using anti-Myc
antibody revealed Myc-sorcin with an apparent molecular mass of 29 kDa,
and anti-sorcin antibodies detected a ~29-kDa transgene-derived
epitope-tagged form of sorcin as well as the 26-kDa endogenous sorcin
(Fig. 1B). We next performed complementary
co-immunoprecipitation analyses of PS2 and Myc-sorcin using
Sorcin was detectable in human temporal cortex by combined
immunoprecipitation-Western blotting analyses using two separate antibodies raised against human sorcin (Fig. 1D). Sorcin in
the human temporal cortex (~28 kDa) exhibited a slightly larger
apparent molecular mass than sorcin in SH-SY5Y cells (~26 kDa),
possibly due to alternative splicing; a molecular mass of ~26-28 kDa
is also slightly larger than the previously reported ~22 kDa (39, 40). To determine whether this endogenous sorcin associates with
endogenous PS2 in vivo, detergent lysates were prepared from human temporal cortex and subjected to co-immunoprecipitation using
Subcellular Localization of the Sorcin-PS2 Molecular
Complex--
To explore the cellular function of the PS2/sorcin
interaction, we next attempted to determine the subcellular locus
wherein the PS2/sorcin interaction occurs. For this purpose, we first visualized sorcin and PS2-CTF in stable PS2-expressing SH-SY5Y cell
lines using double immunofluorescence confocal microscopy (Fig.
2A). PS2 immunoreactivity was
mainly detected in smooth ER/Golgi-like intracellular membrane
compartments, whereas sorcin immunoreactivity was more disperse (Fig.
2A). Sorcin and PS2-CTF co-localized only to a restricted
subcellular region (Fig. 2A, yellow indicates
overlapping signals). Since sorcin is a cytosolic protein (51) and PS2
is a known integral membrane protein (52), we predicted that a subset
of cytosolic sorcin might associate with membranous subcellular
structures to allow the interaction of sorcin with PS2. To locate the
PS2-sorcin interaction, we performed subcellular fractionation using
stable PS2 SH-SY5Y cell lines. After an initial homogenization and
differential centrifugation, sorcin was predominantly found in the
cytosolic fraction, although sorcin immunoreactivity was also
detectable in the heavy membrane fraction, P2 (Fig. 2B). As
predicted, PS2-CTF was absent in the cytosolic fraction and was highly
enriched in the P2 fraction, where membrane-associated sorcin was
detected (Fig. 2B).
To define the specific subcellular membrane compartment where the
PS2/sorcin interaction occurs, total membrane fractions prepared from
SH-SY5Y stably cells expressing wild-type PS2 were further separated
using Nycodenz discontinuous density gradient centrifugation (48, 49).
Each fraction was analyzed by Western blotting using antibodies to PS2
and sorcin (Fig. 2C). The full-length PS2 polypeptide
exhibited virtually identical subcellular distribution to that of
calnexin, a rough ER marker (arrow a, Fig. 2C).
In contrast, the PS2-CTF was visualized in three major peaks: peak one
(fractions 3 and 4), peak two (fractions
6-8), and peak three (fractions 11 and 12)
(Fig. 2C). Sorcin and PS2 were co-localized only to peak one
membrane fractions, indicating that the PS2-sorcin complex was
localized specifically to this subcellular compartment (arrow b, Fig. 2C). In addition, we
performed Western blot analyses using antibodies to multiple
subcellular marker proteins. Interestingly, 19-kDa calcineurin B, a
Ca2+-binding subunit of calcineurin, was distinctively
co-distributed with sorcin in the Nycodenz gradient fractions (Fig.
2C). Membrane-associated sorcin did not appear to
co-localize with the majority of other subcellular markers tested,
including Sorcin Associates with the PS2 Endoproteolytic C-terminal Fragment
but Not with Full-length PS2--
To determine further the PS2 species
that predominantly interacts with sorcin, we co-immunoprecipitated PS2
using anti-sorcin antibodies (Fig.
3A). The levels of PS2-CTF
that co-immunoprecipitated with endogenous sorcin were proportional to
the levels of PS2-CTF detected in total cell lysates (data not shown).
Virtually no full-length PS2 was recovered in the sorcin
immunoprecipitates, confirming that sorcin preferentially interacts
with PS2-CTF (Fig. 3A).
We next tested whether increased accumulation of full-length PS2
affects the interaction between sorcin and PS2. Both treatment with the
proteasome inhibitors MG132 or ALLN (Fig. 3B) and
overexpression of PS2 by transient transfection (data not shown) have
previously been shown to lead to increased levels of full-length PS2
and ubiquitin-positive high molecular weight forms of PS2 but not PS2
endoproteolytic fragments (32, 53). No increase was observed in the
interaction between PS2 and sorcin under either condition. Along with
the subcellular fractionation data, our studies reveal that sorcin
interacts with a subset of the PS2 complexes consisting of the
endoproteolytic fragments but does not interact with full-length PS2.
Elevated Intracellular Calcium Enhances the Sorcin/PS2 Interaction
and Translocation of Sorcin to the Membrane--
We next examined
whether increasing the cytosolic Ca2+ concentration
modulates the sorcin/PS2 interaction. Treatment with the Ca2+ ionophore A23187 did not alter the steady-state levels
of sorcin or PS2 (Fig. 4A).
Meanwhile, the level of sorcin that co-immunoprecipitated with
We report that presenilin 2 interacts endogenously with sorcin, a
modulator of the RyR intracellular Ca2+-releasing channel.
Regulation of ryanodine receptor activity by accessory molecules has
been implicated in synaptic plasticity and other neuronal activities
(43, 54-56). We have also shown that membrane-bound forms of sorcin
co-fractionate with a subset of PS2 endoproteolytic fragments to a
subcellular compartment harboring calcineurin B (Fig. 2C),
another Ca2+-binding molecule that appears to be involved
in the regulation of both inositol 1,4,5-trisphosphate- and
ryanodine-sensitive intracellular Ca2+ channels (57). In
addition, the PS2-sorcin interaction and the translocation of sorcin to
the membrane appear to be increased by elevated intracellular
Ca2+ levels (Fig. 4). These data reveal a molecular link
between PS2 and cellular Ca2+ channels and raise the
possibility that sorcin is recruited by PS2 into a molecular complex
involved in intracellular Ca2+ modulation. In the future,
it will be important to characterize the membranous organelles
harboring the PS2-sorcin complex and to determine whether the
PS2-sorcin complex includes an intracellular Ca2+ channel
(e.g. RyR) as a primary component.
Although other Ca2+-binding proteins have been shown to
interact with PS2, such as calsenilin and calmyrin (26, 27), these interactions were demonstrated only in cells transiently transfected with PS2 cDNAs (26, 27). We (Fig. 3 and Ref. 53) and others (30)
have demonstrated that overexpression of PS2 leads to an accumulation
of full-length PS2, whereas levels of PS2 fragments are reduced or
unchanged. Accordingly, the PS2 species that were found to interact
detectably with calsenilin and calmyrin were full-length PS2 but not
PS2 endoproteolytic fragments (26, 27). Because growing evidence
indicates that the endoproteolytic fragments comprise the functional
units of the presenilins (11, 30), rather than the full-length
proteins, calsenilin and calmyrin most likely play a role in the
proteolysis, trafficking, or stabilization of full-length PS2
intermediates. In contrast, our data show that sorcin interacts with a
subset of PS2 endoproteolytic fragments but not with full-length PS2,
further supporting the possibility that the sorcin-PS2 interaction has
a functional role (i.e. in Ca2+ modulation).
Implications of the sorcin-PS2 interaction for FAD remain to be
elucidated. Since the large hydrophilic loop regions are divergent between PS1 and PS2 and no FAD mutation has been identified in the
putative sorcin binding region of PS2 (synexin homologous domain), the
exact contributions of sorcin and other PS1/PS2 loop-interacting molecules to AD neuropathogenesis have not been fully elucidated (16-19, 58). Interestingly, increased amyloid
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-secretase cleavage of
amyloid
-protein precursor (2-4) and the trafficking/maturation of
other select cellular proteins, including Notch and TrkB (5-8). Common
molecular consequences of presenilin FAD mutations include the
increased production of amyloid
-peptide x-42 and increased
apoptosis (reviewed in Refs. 9-11). In addition, FAD mutations in both
PS1 and PS2 have been shown to disrupt intracellular Ca2+
homeostasis (12, 13). However, the mechanism by which Ca2+
dyshomeostasis contributes to FAD pathogenesis is still unresolved.
- and
-catenin (14-19), p0071 (20), amyloid
-protein precursor (21), filamin/Fh-1 (22), Notch (23), GSK3
(24), Rab11 (25), calsenilin (26), calmyrin
(27), QM/Jif-1 (28), and Bcl-XL (29). It is currently unclear whether these interactions mediate pathogenesis in presenilin FAD. It is also noteworthy that some of these proteins have been shown
to interact either preferentially or exclusively with full-length presenilin over the N- or C-terminal fragments. Since only a subset of
presenilin proteins are cleaved to form stable, functional presenilin
complexes (30-35), and the remaining full-length proteins are degraded
by the proteasome (32, 36-38), proteins that interact with the N-
and/or C-terminal presenilin fragments are more likely to mediate
presenilin function as opposed to maturation of the presenilins.
Additionally, many of these presenilin-interacting proteins have been
identified and characterized using overexpression in cell systems,
whereas only a few have been demonstrated to interact with PS1 and/or
PS2 endogenously (e.g.
-catenin).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
PS2Loop
(30) and
G2L (46). Stable cell lines were maintained in the presence
of 250 µg/ml Zeocin (Invitrogen) as described previously (32).
PS2Loop (30) at 1:2500;
PS1Loop (30) at
1:3000; monoclonal anti-sorcin (39) at 1:2000; and polyclonal
anti-sorcin (47) at 1:10,000. To quantitate relative amounts of
presenilin and sorcin in the blots, Fluor-S MultiImager and
MultiAnalyst software (Bio-Rad) were utilized. Cells or tissues were
lysed using IP buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.25% Nonidet P-40, 2 mM EDTA) plus protease inhibitors, and solubilized proteins
were subjected to immunoprecipitation. For the co-immunoprecipitation
experiments, 0.25-0.5% Nonidet P-40 was utilized, and 0.1% bovine
serum albumin was included. The samples were pre-cleared with protein A
conjugated with magnetic beads (PerSeptive Diagnostics) for 1 h at
4 °C, incubated with antibodies overnight, further incubated with
protein A-magnetic beads (30 µl/sample) for 2 h at 4 °C, and
washed three times with IP buffer. Immunoprecipitates were collected
using a magnetic bead collector, heated to 60 °C in sample buffer,
and subjected to SDS-polyacrylamide gel electrophoresis and Western
blotting. Antibodies used include GM130 (Transduction Laboratories),
calnexin (Stressgene), transferrin receptor (a gift of Dr. I. Trowbridge), APS26 (15) (a gift of Anke Diehlmann and Konrad
Beyreuther), and calcineurin B (Santa Cruz Biotechnology).
PS2loop, and then incubated with
Cy3-conjugated anti-mouse secondary antibodies (Jackson Laboratories)
and Bodipy-conjugated anti-rabbit secondary antibodies (Molecular
Probes). Fluorescent images were captured and analyzed using a Bio-Rad
1024 confocal microscope mounted on a Nikon inverted microscope.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
PS2Loop
antibody (30) in lysates prepared from COS cells transfected with
either Myc-sorcin or a Myc-tagged control protein, Myc-grancalcin, or
Myc-XIAP (Fig. 1C). Only Myc-sorcin was
co-immunoprecipitated by
PS2Loop, indicating that Myc-sorcin
interacts with endogenous PS2 C-terminal (loop) fragments (PS2-CTF)
(Fig. 1C).

View larger version (33K):
[in a new window]
Fig. 1.
Identification of sorcin as an interactor for
the large hydrophilic loop region of PS2. A, homology
between the large hydrophilic loop domain region of PS2 and the
N-terminal region of synexin. Amino acids 319-347 of human PS2 are
compared with amino acids 17-56 of human synexin. Identical residues
are indicated by straight lines and similar residues are
indicated by a + between the sequences. B,
expression and detection of sorcin in stable sorcin cell lines. Human
neuroblastoma SH-SY5Y cells were stably transfected with either empty
vector (vector) or a Myc-tagged sorcin expression construct
(myc-sorcin). The cell lysates were analyzed by Western blot
analyses using anti-Myc (left) or polyclonal anti-sorcin
(right) antibodies. C, identification of the
interaction between sorcin and PS2 using co-immunoprecipitation of
Myc-tagged sorcin and the endogenous PS2 C-terminal fragment (PS2-CTF).
Detergent lysates from COS cells that were transiently transfected with
the constructs indicated in the upper panel were
immunoprecipitated (IP) with
PS2loop and were analyzed by
Western blotting using anti-Myc antibody. Myc-tagged sorcin that
co-immunoprecipitates with endogenous PS2-CTF is indicated by an
arrow. D, detection of sorcin in human
neuroblastoma cells and brain using combined
immunoprecipitation-Western blot analyses. Detergent lysates were
prepared from cultured native SH-SY5Y cells (left) or human
temporal cortex (right), and samples were subjected to
immunoprecipitation with either pre-immune sera or polyclonal
anti-sorcin antibodies and then analyzed by Western blotting with
monoclonal anti-sorcin antibodies. E, co-immunoprecipitation
of sorcin and PS2-CTF in human brain extracts. Temporal cortex tissues
from neurologically normal patients were homogenized, lysed in the
presence of 0.5% Nonidet P-40, and subjected to immunoprecipitation
using
PS2Loop, with
PS1Loop used as a control antibody.
Immunoprecipitates were then analyzed by Western blotting using
polyclonal anti-sorcin antibody. Representative data from five
independent experiments are shown.
PS2Loop antibody or with
PS1Loop (30) as a negative control (Fig.
1E). Endogenous sorcin was recovered from these samples
using only
PS2Loop (Fig. 1E), indicating that sorcin associates with PS2 but not with PS1 in the brain.

View larger version (34K):
[in a new window]
Fig. 2.
Subcellular localization of the sorcin-PS2
complex. A, immunofluorescence confocal microscopy of
sorcin and PS2. Stable SY5Y cell lines expressing wild-type PS2 were
fixed, permeabilized, and double-labeled with either monoclonal
anti-sorcin antibody (red, Cy3) or
PS2loop
(green, Bodipy). B, subcellular distribution of
sorcin in cytosolic and membrane subcellular fractions. Wild-type PS2
stable SH-SY5Y cells were subjected to cell fractionation and
differential centrifugation to yield post-nuclear supernatant
(PNS), cytosol, and heavy (P2, 14,000 × g)
and light (P3, 100,000 × g) membrane fractions. Equal
amounts of protein from each subcellular fraction were analyzed by
Western blotting using monoclonal anti-sorcin antibody or
PS2Loop.
C, subcellular distribution of the sorcin-PS2 complex in
density gradient subcellular fractions. Total membrane fractions from
stable SY5Y cells expressing wild-type PS2 were separated on a
discontinuous Nycodenz gradient. Fractions were collected from the top
using a density gradient fractionator. Equal volumes of each fraction
were analyzed by Western blotting using
PS2loop, monoclonal
anti-sorcin antibody, anti-calcineurin B, and APS26 (anti-PS2 NTF,
where NTF is N-terminal fragment) as well as antibodies to
known subcellular organelle markers, including calnexin, GM130, and
transferrin receptor (Tf-R). Representative data from three
independent experiments are presented.
-adaptin,
-adaptin, clathrin light chain, BAG-1, and
Bcl-2 (data not shown). Neither the Golgi matrix protein GM130 nor the
transferrin receptor co-distributed with sorcin or PS2 (Fig.
2C). These data demonstrate that membrane-associated sorcin
and a subset of PS2 endoproteolytic fragments, but not full-length PS2,
co-localize together to a subcellular compartment that is positive for
calcineurin B. Our data also indicate that the C-terminal
endoproteolytic fragment and full-length forms of PS2 localize to
different subcellular compartments in SH-SY5Y cells (Fig.
2C).

View larger version (27K):
[in a new window]
Fig. 3.
Interaction of sorcin with the C-terminal
endoproteolytic fragment but not with full-length PS2.
A, co-immunoprecipitation (Co-IP) of the PS2 CTF
with endogenous sorcin using anti-sorcin antibody in stable SH-SY5Y
cells. Detergent lysates from stable SH-SY5Y cells expressing vector
(lane 1) or wild-type PS2 (lane 2) were
immunoprecipitated (IP) with monoclonal anti-sorcin
antibodies. The PS2-CTF that co-immunoprecipitated with sorcin was
detected by Western blotting using
PS2Loop (top panel) or
sorcin antibodies (bottom panel). The predicted location of
full-length PS2 is indicated by an arrow (FL).
Other immunoreactivities in the gel derive from mouse IgG light and
heavy chains (*). B, accumulation of the full-length and
high molecular forms of PS2 induced by treatment with proteasome
inhibitors fails to enhance the interaction between PS2 and sorcin.
Stable SH-SY5Y cell lines expressing wild-type PS2 were incubated for
6 h with Me2SO (lanes 1, 4, and
7) or proteasome inhibitors ALLN (lanes 2, 5, and
8) or MG132 (lanes 3, 6, and 9).
Detergent lysates were subjected to co-immunoprecipitation using
PS2loop. Immunoprecipitates along with straight cell lysates (20 µg each; lanes 7-9) were analyzed by Western blot
analyses using the antibodies indicated in the bottom
panels. The locations of full-length PS2 and the normal and
alternative PS2 C-terminal fragments are indicated by
arrows.
PS2Loop greatly increased as the result of A23187 treatment (Fig.
4A). To explore the possibility that Ca2+
mediates the translocation of the sorcin-PS2 complex, we examined the
subcellular distribution of membrane-associated sorcin in PS2-expressing cells that were grown in the presence or absence of
A23187. Although A23187 did not alter the subcellular distribution of
the sorcin-PS2 complex, we found that A23187 treatment led to increased
association of sorcin with the membrane (Fig. 4B). Our
studies demonstrate that sorcin is translocated from the cytosol to the
membrane when cytosolic Ca2+ is elevated by this ionophore,
indicating that the recruitment of sorcin into a molecular complex
harboring PS2 is modulated by intracellular Ca2+
levels.

View larger version (22K):
[in a new window]
Fig. 4.
Elevated intracellular calcium enhances the
association of sorcin with PS2 and the recruitment of sorcin to the
membrane. A, treatment with the calcium ionophore
A23187 increases the binding between sorcin and PS2. SY5Y cells stably
expressing wild-type PS2 were grown in the presence of
Me2SO (lanes 1 and 3) or 20 µM A23187 for 3 h, and detergent lysates were
subjected to co-immunoprecipitation using
PS2loop. The amount of
sorcin that co-immunoprecipitated with PS2-CTF was greatly enhanced by
treatment with A23187, whereas the total amount of sorcin in the
lysates remained unchanged. B, A23187 treatment increases
the association of sorcin with membrane fractions. Stable PS2 SY5Y
cells were grown in the above-mentioned conditions and were subjected
to subcellular fractionation as described in Fig. 2. Equal volumes of
each fraction were analyzed by Western blot analyses using sorcin
antibodies, and sorcin immunoreactivities were normalized to the unit
membrane protein in the subcellular fractions and plotted.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-peptide levels can
result from RyR-driven elevations in intracellular Ca2+
(59). On the other hand, decreased RyR activity correlates with early
pathological changes in AD (60). To this end, we are currently
investigating whether the sorcin/PS2 interaction is involved in either
Ca2+-related increases in amyloid
-peptide or observed
defects in RyR activity in AD. In any event, our study implies that the
sorcin/PS2 interaction may play a normal and/or pathological role in
intracellular Ca2+ homeostasis.
| |
ACKNOWLEDGEMENTS |
|---|
We thank L. Kanaley-Andrews and E. Bird at the Harvard Brain Tissue Resources Center for postmortem brain tissues; M. Kim for helpful discussions; T. Z. Grenfell and A. J. Saunders for critical review of the manuscript; and G. Thinakaran, S. Sisodia, T. Tomita, T. Iwatsubo, A. Diehlmann, K. Beyreuther, and I. Trowbridge for antibodies.
| |
FOOTNOTES |
|---|
* This work was supported in part by NIA grants from the National Institutes of Health and the Alzheimer's Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Kenner Fellow of the American Heart Association.
** Howard Hughes Medical Institute Medical Student Training Fellow.

Recipient of the Partners Investigator (Nesson) award. To whom
correspondence should be addressed. Tel.: 617-726-3739; Fax: 617-726-5677; E-mail: kim@helix.mgh.harvard.edu.
Published, JBC Papers in Press, March 15, 2000, DOI 10.1074/jbc.M909882199
| |
ABBREVIATIONS |
|---|
The abbreviations used are: FAD, familial Alzheimer's disease; AD, Alzheimer's disease; CTF, C-terminal fragment; PS1, presenilin 1; PS2, presenilin 2; RyR, ryanodine receptor.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Tanzi, R. E., Kovacs, D. M., Kim, T.-W., Moir, R. D., Guenette, S. Y., and Wasco, W. (1996) Neurobiol. Dis. 3, 159-168 |
| 2. | De Strooper, B., Saftig, P., Craessaerts, K., Vandersticheles, H., Guhde, G., Annaert, W., Von Figura, K., and Van Leuven, F. (1998) Nature 391, 387-390 |
| 3. | Steiner, H., Duff, K., Capell, A., Romig, H., Grim, M. G., Lincoln, S., Hardy, J., Yu, X., Picciano, M., Fechteler, K., Citron, M., Kopan, R., Pesold, B., Keck, S., Baader, M., Tomita, T., Iwatsubo, T., Baumeister, R., and Haass, C. (1999) J. Biol. Chem. 274, 28669-28673 |
| 4. | Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. (1999) Nature 398, 513-517 |
| 5. | De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., Goate, A., and Kopan, R. (1999) Nature 398, 518-222 |
| 6. | Struhl, G., and Greenwald, I. (1999) Nature 398, 522-525 |
| 7. | Ye, Y., Lukinova, N., and Fortini, M. E. (1999) Nature 398, 525-529 |
| 8. | Naruse, S., Thinakaran, G., Luo, J.-J., Kusiak, J. W., Tomita, T., Iwatsubo, T., Qian, X., Ginty, D. D., Price, D. L., Borchelt, D. R., Wong, P. C., and Sisodia, S. S. (1998) Neuron 21, 1213-1221 |
| 9. | Hardy, J. (1997) Trends Neurosci. 20, 154-159 |
| 10. | Selkoe, D. J. (1998) Trends Cell Biol. 8, 447-453 |
| 11. | Thinakaran, G. (1999) J. Clin. Invest. 104, 1321-1327 |
| 12. | Guo, Q., Furukawa, K., Sopher, B. L., Pham, D. G., Xie, J., Robinson, N., Martin, G. M., and Mattson, M. P. (1996) Neuroreport 8, 379-383 |
| 13. | Leissring, M. A., Parker, I., and LaFerla, F. M. (1999) J. Biol. Chem. 274, 32535-32538 |
| 14. | Zhou, J., Liyanage, U., Medina, M., Ho, C., Simmons, A. D., Lovett, M., and Kosik, K. S. (1997) Neuroreport 8, 2085-2090 |
| 15. | Tesco, G., Kim, T.-W., Diehlmann, A., Beyreuther, K., and Tanzi, R. E. (1998) J. Biol. Chem. 273, 33909-33914 |
| 16. | Zhang, Z., Hartmann, H., Do, V. M., Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., van de Wetering, M., Clevers, H., Saftig, P., De Strooper, B., He, X., and Yankner, B. A. (1998) Nature 395, 698-702 |
| 17. | Murayama, M., Tanaka, S., Palacino, J., Murayama, O., Honda, T., Sun, X., Yasutake, K., Nihonmatsu, N., Wolozin, B., and Takashima, A. (1998) FEBS Lett. 433, 73-77 |
| 18. | Nishimura, M, Yu, G., Levesque, G., Zhang, D. M., Ruel, L., Chen, F., Milman, P., Holmes, E., Liang, Y., Kawarai, T., Jo, E., Supala, A., Rogaeva, E., Xu, D.-M., Janus, C., Levesque, L., Bi, Q., Duthie, M., Rozmahel, R., Mattila, K., Lannfelt, L., Westaway, D., Mount, H. T. J., Woodgett, J., Fraser, P. E., and St. George-Hyslop, P. (1999) Nat. Med. 5, 164-169 |
| 19. | Kang, D. E., Soriano, S., Frosch, M. P., Collins, T., Naruse, S., Sisodia, S. S., Leibowitz, G., Levine, F., and Koo, E. H. (1999) J. Neurosci. 19, 4229-4237 |
| 20. | Stahl, B., Diehlmann, A., and Südhof, T. C. (1999) J. Biol. Chem. 274, 9141-9148 |
| 21. | Xia, W., Zhang, J., Perez, R., Koo, E. H., and Selkoe, D. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 8208-8213 |
| 22. | Zhang, W., Han, S. W., McKeel, D. W., Goate, A., and Wu, J. Y. (1998) J. Neurosci. 18, 914-922 |
| 23. | Ray, W. J., Yao, M., Nowotny, P., Mumm, J., Zhang, W., Wu, J. Y., Kopan, R., and Goate, A. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3263-3268 |
| 24. | Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Yamaguchi, H., Sugihara, S., and Wolozin, B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9637-9641 |
| 25. | Dumanchin, C., Czech, C., Campion, D., Cuif, M. H., Poyot, T., Martin, C., Charbonnier, F., Goud, B., Pradier, L., and Frebourg, T. (1999) Hum. Mol. Genet. 8, 1263-1269 |
| 26. | Buxbaum, J. D., Choi, E.-K., Luo, Y., Lilliehook, C., Crowley, A. C., Merriam, D. E., and Wasco, W. (1998) Nat. Med. 4, 1177-1181 |
| 27. | Stabler, S. M., Ostrowski, L. L., Janicki, S. M., and Monteiro, M. J. (1999) J. Cell Biol. 145, 1277-1292 |
| 28. | Imafuku, I., Masaki, T., Waragai, M., Takeuchi, S., Kawabata, M., Hirai, S.-I., Ohno, S., Nee, L. E., Lippa, C. F., Kanazawa, I., Imagawa, M., and Okazawa, H. (1999) J. Cell Biol. 147, 121-133 |
| 29. | Passer, B. J., Pellegrini, L., Vito, P., Ganjei, J. K., and D'Adamio, L. (1999) J. Biol. Chem. 274, 24007-24013 |
| 30. | Thinakaran, G., Borcehlt, D., Lee, M., Slunt, H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., Hardy, J., Levey, A. L., Gandy, S. E., Jenkinds, N. A., Copeland, N. G., Price, D., L., and Sisodia, S. S. (1996) Neuron 17, 181-190 |
| 31. | Mercken, M., Takahashi, H., Honda, T., Sato, K., Murayama, M., Nakazato, Y., Noguchi, K., Imahori, K., and Takashima, A. (1996) FEBS Lett. 389, 297-303 |
| 32. | Kim, T.-W., Pettingell, W. H., Hallmark, O. G., Moir, R. D., Wasco, W., and Tanzi, R. E. (1997) J. Biol. Chem. 272, 11006-11010 |
| 33. | Seeger, M., Nordstedt, C., Petanceska, S., Kovacs, D. M., Gouras, G. K., Hahne, S., Fraser, P., Levesque, L., Czernik, A. J., St. George-Hyslop, P., Sisodia, S. S., Thinakaran, G., Tanzi, R. E., Greengard, P., and Gandy, P. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5090-5094 |
| 34. | Thinakaran, G., Regard, J. B., Bouton, C. M. L., Harris, C. L., Price, D. L., Borchelt, D. R., and Sisodia, S. S. (1998) Neurobiol. Dis. 4, 438-453 |
| 35. | Capell, A., Grünberg, J., Pesold, B., Diehlmann, A., Citron, M., Nixon, R., Beyreuther, K., Selkoe, D. J., and Haass, C. (1998) J. Biol. Chem. 273, 3205-3211 |
| 36. | Marambaud, P., Ancolio, K., Lopez-Perez, E., and Checler, F. (1998) Mol. Med. 4, 147-157 |
| 37. | Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Takahashi, H., Murayama, O., Murayama, M., Sato, K., Omori, A., Tsubuki, S., Saido, T. C., and Takashima, A. (1999) J. Neurochem. 72, 255-261 |
| 38. | Fraser, P. E., Levesque, G., Yu, G., Mills, L. R., Thirwell, J., Frantseva, M., Gandy, S. E., Seeger, M., Carlen, P. L., and St. George-Hyslop, P. (1998) Neurobiol. Aging 19, 19-21 |
| 39. | Meyers, M. B., Pickel, V. M., Sheu, S.-S., Sharma, V. K., Scotto, K. W., and Fishman, G. I. (1995) J. Biol. Chem. 270, 26411-26418 |
| 40. | Van der Bliek, A. M., Meyers, M. B., Biedler, J. L., Hes, E., and Borst, P. (1986) EMBO J. 5, 3201-3208 |
| 41. | Maki, M., Narayama, S. V. L., and Hitomi, K. (1997) Biochem. J. 328, 718-720 |
| 42. | Lokuta, A. J., Meyers, M. B., Sanders, P. R., Fishman, G. I., and Valdivia, H. H. (1997) J. Biol. Chem. 272, 25333-25338 |
| 43. | Valdivia, H. H. (1998) Trends Pharmacol. Sci. 19, 479-482 |
| 44. | Pickel, V. M., Clarke, C. L., and Meyers, M. B. (1997) J. Comp. Neurol. 386, 625-634 |
| 45. | Boyhan, A., Casimir, C. M., French, J. K., Teahan, C. G., and Segal, A. W. (1992) J. Biol. Chem. 267, 2928-2933 |
| 46. | Tomita, T., Maruyama, K., Saido, T. C., Kume, H., Shinozaki, K., Tokuhiro, S., Capell, A., Walter, J., Grünberg, J., Haass, C., Iwatsubo, T., and Obata, K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2025-2030 |
| 47. | Brownawell, A. M., and Creutz, C. E. (1997) J. Biol. Chem. 272, 22182-22190 |
| 48. | Hammond, C., and Helenius, A. (1994) J. Cell Biol. 126, 41-52 |
| 49. | Kim, M., Velier, J., Chase, K., Laforet, G., Kalchman, M. A., Hayden, M. R., Won, L., Heller, A., Aronin, N., and DiFiglia, M. (1999) Neuroscience 89, 1159-1167 |
| 50. | Creutz, C. E. (1992) Science 258, 924-931 |
| 51. | Meyers, M. B., Zamparelli, C., Verzili, D., Dicker, A. P., Blanck, T. J., and Chiancone, E. (1995) FEBS Lett. 357, 230-234 |
| 52. | Doan, A., Thinakaran, G., Borchelt, D. R., Slunt, H. H., Ratovitsky, T., Podlisny, M., Selkoe, D. J., Seeger, M., Gandy, S. E., Price, D. L., and Sisodia, S. S. (1996) Neuron 7, 1023-1030 |
| 53. | Kim, T.-W., Pettingell, W. H., Jung, Y.-K., Kovacs, D. M., and Tanzi, R. E. (1997) Science 277, 373-376 |
| 54. | Alkon, D. L., Nelson, T. J., Zhao, W., and Cavallaro, S. (1998) Trends Neurosci. 21, 529-537 |
| 55. | Berridge, M. J. (1998) Neuron 21, 13-26 |
| 56. | Balschun, D., Wolfer, D. P., Bertocchini, F., Barone, B., Conti, A., Zuschratter, W., Missiaen, L., Lipp, H.-P., Frey, J. U., and Sorrentino, V. (1999) EMBO J. 18, 5264-5273 |
| 57. | Cameron, A. M., Steiner, J. P., Roskams, A. J., Ali, S. M., Ronnett, G. V., and Snyder, S. H. (1995) Cell 83, 463-472 |
| 58. | Saura, C. A., Taisuke, T., Iwatsubo, T., and Thinakaran, G. (1999) Soc. Neurosci. Abstr. 25, 56 |
| 59. | Querfurth, H. W., Jiang, J., Geiger, J. D., and Selkoe, D. J. (1997) J. Neurochem. 69, 1580-1591 |
| 60. | Kelliher, M., Fastbom, J., Cowburn, R. F., Bonkale, W., Ohm, T. G., Ravid, R., Sorrentino, V., and O'Neill, C. (1999) Neuroscience 92, 499-513 |
This article has been cited by other articles:
![]() |
L. P. Collis, M. B. Meyers, J. Zhang, C. K. L. Phoon, E. A. Sobie, W. A. Coetzee, and G. I. Fishman Expression of a sorcin missense mutation in the heart modulates excitation-contraction coupling FASEB J, February 1, 2007; 21(2): 475 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Kang, I. S. Yoon, E. Repetto, T. Busse, N. Yermian, L. Ie, and E. H. Koo Presenilins Mediate Phosphatidylinositol 3-Kinase/AKT and ERK Activation via Select Signaling Receptors: SELECTIVITY OF PS2 IN PLATELET-DERIVED GROWTH FACTOR SIGNALING J. Biol. Chem., September 9, 2005; 280(36): 31537 - 31547. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Verkhratsky Physiology and Pathophysiology of the Calcium Store in the Endoplasmic Reticulum of Neurons Physiol Rev, January 1, 2005; 85(1): 201 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shibata, K. Yamada, T. Mizuno, C. Yorikawa, H. Takahashi, H. Satoh, Y. Kitaura, and M. Maki The Penta-EF-Hand Protein ALG-2 Interacts with a Region Containing PxY Repeats in Alix/AIP1, Which Is Required for the Subcellular Punctate Distribution of the Amino-Terminal Truncation Form of Alix/AIP1 J. Biochem., January 1, 2004; 135(1): 117 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Meyers, A. Fischer, Y.-J. Sun, C. M. B. Lopes, T. Rohacs, T. Y. Nakamura, Y.-Y. Zhou, P. C. Lee, R. A. Altschuld, S. A. McCune, et al. Sorcin Regulates Excitation-Contraction Coupling in the Heart J. Biol. Chem., August 1, 2003; 278(31): 28865 - 28871. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mella, G. Colotti, C. Zamparelli, D. Verzili, A. Ilari, and E. Chiancone Information Transfer in the Penta-EF-hand Protein Sorcin Does Not Operate via the Canonical Structural/Functional Pairing: A STUDY WITH SITE-SPECIFIC MUTANTS J. Biol. Chem., June 27, 2003; 278(27): 24921 - 24928. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Meyer, N. Strutz, L. C. Gahring, and S. W. Rogers Glutamate Receptor Subunit 3 Is Modified by Site-specific Limited Proteolysis Including Cleavage by {gamma}-Secretase J. Biol. Chem., June 20, 2003; 278(26): 23786 - 23796. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kitagawa, S. Shimohama, T. Oeda, K. Uemura, R. Kohno, A. Kuzuya, H. Shibasaki, and N. Ishii The Role of the Presenilin-1 Homologue Gene sel-12 of Caenorhabditis elegans in Apoptotic Activities J. Biol. Chem., March 28, 2003; 278(14): 12130 - 12134. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Morohashi, N. Hatano, S. Ohya, R. Takikawa, T. Watabiki, N. Takasugi, Y. Imaizumi, T. Tomita, and T. Iwatsubo Molecular Cloning and Characterization of CALP/KChIP4, a Novel EF-hand Protein Interacting with Presenilin 2 and Voltage-gated Potassium Channel Subunit Kv4 J. Biol. Chem., April 19, 2002; 277(17): 14965 - 14975. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xie, M. D. Dwyer, L. Swenson, M. H. Parker, and M. C. Botfield Crystal structure of calcium-free human sorcin: A member of the penta-EF-hand protein family Protein Sci., December 1, 2001; 10(12): 2419 - 2425. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tanahashi and T. Tabira Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein Hum. Mol. Genet., September 1, 2000; 9(15): 2281 - 2289. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-K. Choi, N. F. Zaidi, J. S. Miller, A. C. Crowley, D. E. Merriam, C. Lilliehook, J. D. Buxbaum, and W. Wasco Calsenilin Is a Substrate for Caspase-3 That Preferentially Interacts with the Familial Alzheimer's Disease-associated C-terminal Fragment of Presenilin 2 J. Biol. Chem., May 25, 2001; 276(22): 19197 - 19204. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Lee, K.-M. Jung, Y. Z. Huang, L. B. Bennett, J. S. Lee, L. Mei, and T.-W. Kim Presenilin-dependent gamma -Secretase-like Intramembrane Cleavage of ErbB4 J. Biol. Chem., February 15, 2002; 277(8): 6318 - 6323. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||